Max Gelman

Reporting on pharma and biotech, @endpts. Baseball fan, Northwestern alum. Email: [email protected]

[Max Gelman @MaxGelman]

Neumora fail: First Phase 3 for depression drug is an unequivocal miss. The company is still running two other identical Phase 3 trials, @ky_lahucik has the latest. $NMRA -79%

https://t.co/MFdJpOjqC9

[Max Gelman @MaxGelman]

Vanza triple PR: https://t.co/jryDnf0WxC

[Max Gelman @MaxGelman]

FDA approved Vertex's "vanza triple" formulation for cystic fibrosis, and new mutations for Trikafta. Both come with boxed warnings https://t.co/5oDyd49ZM2

[Elizabeth Cairns @ByLizC]

Now updated and with new version of the chart!

$NVO $LLY $VKTX $RHHBY

[Ryan Cross the Science Boss @RLCscienceboss]

This will be one to watch. Sorriso says it has figured out how to make an orally-administered antibody, and is claiming success in Phase 1b study in ulcerative colitis. @MaxGelman has the details for @endpts - https://t.co/i7rYNofAVb

[Max Gelman @MaxGelman]

Sarepta has a long & controversial history of getting Duchenne drugs OK’d w/accelerated approval. Now it will try in more rare diseases.

"We will apply that same focus and creative energy and patient-mission approach to these therapies," the CEO said.

https://t.co/Eogl6UgnKh

[Max Gelman @MaxGelman]

The FDA has approved BridgeBio's rare heart disease drug, notably including mortality on the label. BridgeBio will brand the drug as Attruby, and it will cost about $245K per year. $BBIO

https://t.co/lOJfkM1yLD

[Max Gelman @MaxGelman]

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

https://t.co/Mu5fu9v3TW

[Max Gelman @MaxGelman]

Sage reports Phase 2 failure in Huntington's disease, ends drug's development $SAGE

https://t.co/X7TjhLoJIQ

[Max Gelman @MaxGelman]

NEW: Me and @RLCscienceboss took a look at how Sage's upcoming Huntington's readout could be its last, best hope at turning the ship around

https://t.co/uW3JTprc5i

[Max Gelman @MaxGelman]

Re-upping my piece from last week on a potential FDA commissioner under an RFK Jr.-led HHS

[Max Gelman @MaxGelman]

Biotech industry worries over potential for RFK Jr. ally as FDA pick

https://t.co/H6iXZYc9iJ

[Max Gelman @MaxGelman]

Biotech industry worries over potential for RFK Jr. ally as FDA pick

https://t.co/H6iXZYc9iJ

[Eric Topol @EricTopol]

Two outstanding pieces by @kakape on misinformation, open-access, @ScienceMagazine
https://t.co/FD8sQQtQQ0
https://t.co/zuLeK5PWGo

[Max Gelman @MaxGelman]

Hints of impatience grow with Biogen as it tries to find a bridge to growth

https://t.co/u9nk7fPH8t

[Zach Brennan @ZacharyBrennan]

What would RFK Jr. do on healthcare? Trump ally's FDA plans raise alarm - https://t.co/v4X6854xVV

[Max Gelman @MaxGelman]

NEW: Eli Lilly says a slightly tweaked dosing regimen of its Alzheimer's drug Kisunla can lower the rate of brain swelling side effects

https://t.co/qxhguGIK32

[Kyle LaHucik @ky_lahucik]

Evergreen reminder to always double check who you’re emailing before hitting send

Ex-Pfizer CFO emailed CEO Albert Bourla over the weekend. The message was blank. But the “to” field included a rep for activist Starboard

From @ArmstrongDrew @maxonwifi

https://t.co/Z6p5IRWcGq

[Nicole DeFeudis @Nicole_DeFeudis]

This year’s Women in Biopharma R&D report is dedicated to Natalie Grover, who launched the project with @AmberTongPW in 2019 while they were working at Endpoints. We’re proud to continue their tradition of honoring 20 exceptional women leaders.

https://t.co/g7aeAVvPGl

[Max Gelman @MaxGelman]

FDA approves first new schizophrenia drug in decades --> drug was centerpiece of Bristol Myers Squibb's $14B buyout of Karuna $BMY

https://t.co/qVx3cXvZNy

[Max Gelman @MaxGelman]

The Federal Reserve cut interest rates by 50 bps. What does that mean for biotech, pharma and venture capital? https://t.co/gCgSG5nZmD